US4479932A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Brain-specific drug delivery
Assignee: University of Florida
•
Filing: 1982-05-18
•
Granted: 1984-10-30
•
Expires: 2002-05-18
Abstract
Abstract Centrally acting drug species are site-specifically/sustainedly delivered to the brain by administering to a patient in need of such treatment a therapeutically effective amount of the target drug species [D] tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine-><-pyridinium salt type redox carrier. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type drug/carrier entity [D-QC]+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, and subsequent cleavage of the quaternary carrier/drug species results in sustained delivery of the drug [D] in the brain and facile elimination of the carrier moiety [QC]+.
Inventors
- 👤 Nicholas S. Bodor
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 06:02
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; C07D213/79; C07D213/80; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/54; A61K47/559; A61P; A61P25/00; A61P25/28; A61P43/00; C07D209/00; C07D209/02; C07D209/04; C07D209/30; C07D209/32; C07D211/00; C07D211/04; C07D211/80; C07D211/84; C07D211/90; C07D213/81; C07D213/82; C07D401/00; C07D401/02; C07D401/12; C07J; C07J43/00; C07J43/003; C07K; C07K14/00; C07K14/435; C07K14/665; C07K14/70; A61K38/00
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
13 words
A compound having the formula ##STR47## wherein R is lower alkyl or benzyl.
Claim 2
Dependent Claim
13 words
A compound having the formula ##STR47## wherein R is lower alkyl or benzyl.
Claim 3
Dependent Claim
11 words
The compound as defined by claim 1, wherein R is methyl.
Claim 4
Dependent Claim
18 words
A pyridinium salt, the cation of which has the formula ##STR48## wherein R is lower alkyl or benzyl.
Claim 5
Dependent Claim
18 words
A pyridinium salt, the cation of which has the formula ##STR48## wherein R is lower alkyl or benzyl.
Claim 6
Dependent Claim
11 words
A salt as defined by claim 3, wherein R is methyl.
Claim 7
Dependent Claim
43 words
A method of site-specifically/sustainedly delivering testosterone to the brain, said method comprising administering to an animal in need of such treatment a quantity of a compound as claimed in claim 1 sufficient to release a pharmacologically effective amount of testosterone to the brain.
Claim 8
Dependent Claim
19 words
A pharmaceutical composition of matter comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 9
Dependent Claim
55 words
A pharmaceutical composition of matter, in unit dosage form, for use in delivering a pharmacologically effective amount of testosterone to the brain, said composition comprising: (i) an amount of a compound as claimed in claim 1 sufficient to release a pharmacologically effective amount of testosterone to the brain; and (ii) a pharmaceutically acceptable carrier therefor.
Claim 10
Dependent Claim
63 words
A compound adapted for the site-specific/sustained delivery of a centrally acting drug species to the brain, said compound having the formula ##STR49## wherein R is lower alkyl or benzyl and D is the residue of the drug phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine, said residue being characterized by the absence of a hydrogen atom from the --NH 2 functional group in said drug.
Claim 11
Dependent Claim
63 words
A compound adapted for the site-specific/sustained delivery of a centrally acting drug species to the brain, said compound having the formula ##STR49## wherein R is lower alkyl or benzyl and D is the residue of the drug phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine, said residue being characterized by the absence of a hydrogen atom from the --NH 2 functional group in said drug.
Claim 12
Dependent Claim
11 words
A compound as defined by claim 8, wherein R is methyl.
Claim 13
Dependent Claim
14 words
A compound as defined by claim 8, wherein D is the residue of phenethylamine.
Claim 14
Dependent Claim
11 words
The compound as defined by claim 10, wherein R is methyl.
Claim 15
Dependent Claim
14 words
A compound as defined by claim 8, wherein D is the residue of amphetamine.
Claim 16
Dependent Claim
14 words
A compound as defined by claim 8, wherein D is the residue of dextroamphetamine.
Claim 17
Dependent Claim
14 words
A compound as defined by claim 8, wherein D is the residue of levamphetamine.
Claim 18
Dependent Claim
14 words
A compound as defined by claim 8, wherein D is the residue of phentermine.
Claim 19
Dependent Claim
52 words
A pyridinium salt, the cation of which has the formula ##STR50## wherein R is lower alkyl or benzyl and D is the residue of the drug phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine, said residue being characterized by the absence of a hydrogen atom from the --NH 2 functional group in said drug.
Claim 20
Dependent Claim
52 words
A pyridinium salt, the cation of which has the formula ##STR50## wherein R is lower alkyl or benzyl and D is the residue of the drug phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine, said residue being characterized by the absence of a hydrogen atom from the --NH 2 functional group in said drug.
Claim 21
Dependent Claim
11 words
A salt as defined in claim 16, wherein R is methyl.
Claim 22
Dependent Claim
14 words
A salt as defined by claim 16, wherein D is the residue of phenethylamine.
Claim 23
Dependent Claim
14 words
A salt as defined by claim 16, wherein D is the residue of amphetamine.
Claim 24
Dependent Claim
14 words
A salt as defined by claim 16, wherein D is the residue of dextroamphetamine.
Claim 25
Dependent Claim
14 words
A salt as defined by claim 16, wherein D is the residue of levamphetamine.
Claim 26
Dependent Claim
14 words
A salt as defined by claim 16, wherein D is the residue of phentermine.
Claim 27
Dependent Claim
54 words
A method for site-specifically/sustainedly delivering phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine to the brain, said method comprising administering to an animal in need of such treatment a quantity of a compound as claimed in claim 8 sufficient to release a pharmacologically effective amount of phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine, respectively, to the brain.
Claim 28
Dependent Claim
19 words
A pharmaceutical composition of matter comprising a compound as claimed in claim 8 and a pharmaceutically acceptable carrier therefor.
Claim 29
Dependent Claim
66 words
A pharmaceutical composition of matter, in unit dosage form, for use in delivering a pharmacologically effective amount of phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine to the brain, said composition comprising: (i) an amount of a compound as claimed in claim 8 sufficient to release a pharmacologically effective amount of phenethylamine, amphetamine, dextroamphetamine, levamphetamine or phentermine, respectively, to the brain; and (ii) a pharmaceutically acceptable carrier therefor.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-10-30 | 1988-04-30 | 1988-10-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-10-30 | 1992-04-30 | 1992-10-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-10-30 | 1996-04-30 | 1996-10-30 | $7700.00 | Window Closed / Lapsed |